Provider: Pechala's Reports
Ruthigen Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ruthigen Inc announces pricing of initial public offering
Ruthigen Inc:Pricing of initial public offering of 2,650,000 units, which reflects increase in originally anticipated number of units, with each unit consisting of one share of common stock and one Series A Warrant.Each Series A Warrant is exercisable for one share of common stock and one Series B Warrant to purchase one share of common stock.All of units are being offered by Ruthigen at initial public offering price of $7.25 per unit.Units will not be certificated and shares of common stock and Series A Warrants may be transferred separately immediately upon issuance.Dawson James Securities, Inc. is acting as sole book-running manager for the underwritten offering.
Latest Developments for Ruthigen Inc
Latest Key Developments in Biotechnology
- Advaxis Inc completes $17 mln financing
- FDA accepts IND application for Radius Health's investigational drug RAD1901 being developed for potential use in Metastatic Breast Cancer
- Amarantus BioScience Holdings, Inc submits orphan drug designation application to US FDA for treatment of Retinal Artery occlusion with product candidate MANF
- Carna Biosciences Inc expects extraordinary loss for Q4 2014 and issues consolidated full-year outlook for FY 2014
- Share this
- Digg this